Synthesis, structure and solution chemistry of mixed-ligand oxovanadium(IV) and oxovanadium(V) complexes incorporating tridentate ONO donor hydrazone ligands

In the title family, the ONO donor ligands are the acetylhydrazones of salicylaldehyde (H₂L¹) and 2-hydroxyacetophenone (H₂L²) (general abbreviation, H₂L). The reaction of bis(acetylacetonato)oxovanadium(IV) with a mixture of tridentate H₂L and a bidentate NN donor [e.g., 2,2′-bipyridine(bpy) or 1,10-phenanthroline(phen), hereafter B] ligands in equimolar ratio afforded the tetravalent complexes of the type [V^IVO(L)(B)]; complexes (1)-(4) whereas, if B is replaced by 8-hydroxyquinoline(Hhq) (which is a bidentate ON donor ligand), the above reaction mixture yielded the pentavalent complexes of the type [V^VO(L)(hq)]; complexes (5) and (6). Aerial oxygen is most likely the oxidant (for the oxidation of V^IV → V^V) in the synthesis of pentavalent complexes (5) and (6). [V^IVO(L)(B)] complexes are one electron paramagnetic and display axial EPR spectra, while the [V^VO(L)(hq)] complexes are diamagnetic. The X-ray structure of [V^VO(L²)(hq)] (6) indicates that H₂L² ligand is bonded with the vanadium meridionally in a tridentate dinegative fashion through its phenolic-O, enolic-O and imine-N atoms. The general bond length order is: oxo < phenolato < enolato. The V-O (enolato) bond is longer than V-O (phenolato) bond by ∼0.07 Å and is identical with V-O (carboxylate) bond. ¹H NMR spectrum of (6) in CDCl₃ solution indicates that the binding nature in the solid state is also retained in solution. Complexes (1)-(4) display two ligand-field transitions in the visible region near 820 and 480 nm in DMF solution and exhibit irreversible oxidation peak near +0.60 V versus SCE in DMSO solution, while complexes (5) and (6) exhibit only LMCT band near 535 nm and display quasi-reversible one electron reduction peak near −0.10 V versus SCE in CH₂Cl₂ solution. The VO³⁺-VO²⁺E_1/2 values shift considerably to more negative values when neutral NN donor is replaced by anionic ON donor species and it also provides better VO³⁺ binding via phenolato oxygen. For a given bidentate ligand, E_1/2 increases in the order: (L²)²⁻ < (L¹)²⁻.     

Reduction of vanadium(V) with ascorbic acid and isolation of the generated oxovanadium(IV) species

The interaction of sodium metavanadate and VOCl₃ with ascorbic acid, one of the possible natural reducing agents of vanadium(V) to oxovanadium(IV), has been investigated. Three new VO²⁺ complexes could be isolated as microcrystalline powders. One of them, of composition K_1.5Na_0.5[VO(HAsc)(OH)₃], contains ascorbic acid as a monodentate ligand. In the other two, K[VO(Diketo)(OH)]·H₂O and Na₃[VO(Diketo)₂(OH)], the enolized form of 2,3-diketogulonic acid (one of the oxidation products of ascorbic acid), acts as a bidentate ligand. The complexes were characterized by means of electronic (absorption and reflectance) and infrared spectroscopy and magnetic susceptibility measurements. Their thermal behavior was investigated by thermogravimetric and differential thermal analyses. The interest of the investigated system in relation to vanadium detoxification is also discussed.     

Metallokinetic characteristics of antidiabetic bis(allixinato)oxovanadium(IV)-related complexes in the blood of rat

The antidiabetic effect of vanadium is a widely accepted phenomenon; some oxovanadium(IV) complexes have been found to normalize high blood glucose levels in both type 1 and type 2 diabetic animals. In light of the future clinical use of these complexes, the relationship among their chemical structures, physicochemical properties, metallokinetics, and antidiabetic activities must be closely investigated. Recently, we found that among bis(3-hydroxypyronato)oxovanadium(IV) [VO(3hp)₂] related complexes, bis(allixinato)oxovanadium(IV) [VO(alx)₂] exhibits a relatively strong hypoglycemic effect in diabetic animals. Next, we examined its metallokinetics in the blood of rats that received five VO(3hp)₂-related complexes by the blood circulation monitoring–electron paramagnetic resonance method. The metallokinetic parameters were obtained from the blood clearance curves based on a two-compartment model; most parameters, such as area under the concentration curve and mean residence time, correlated significantly with the in vitro insulinomimetic activity in terms of 1/IC₅₀ (IC₅₀ is the 50% inhibitory concentration of the complex required for the release of free fatty acids in adipocytes) and the lipophilicity of the complex (log P _com). The oxovanadium(IV) concentration was significantly higher and the species resided longer in the blood of rats that received VO(alx)₂ than in the blood of rats that received VO(3hp)₂ or bis(kojato)oxovanadium(IV); VO(alx)₂ also exhibited higher log P _com and 1/IC₅₀ values. On the basis of these results, we propose that the introduction of lipophilic groups at the C2 and C6 positions of the 3hp ligand is an effective method to enhance the hypoglycemic effect of the complexes, as supported by the observed in vivo exposure and residence in the blood.     

Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin

Bis(maltolato)oxovanadium(IV) (BMOV), and its ethylmaltol analog, bis(ethylmaltolato)oxovanadium(IV) (BEOV), are candidate insulin-enhancing agents for the treatment of type 2 diabetes mellitus; in mid-2008, BEOV advanced to phase II clinical testing. The interactions of BMOV and its inorganic congener, vanadyl sulfate (VOSO₄), with human serum apo-transferrin (hTf) were investigated using differential scanning calorimetry (DSC). Addition of BMOV or VOSO₄ to apo-hTf resulted in an increase in thermal stability of both the C- and N-lobes of transferrin as a result of binding to either vanadyl compound. A series of DSC thermograms of hTf solutions containing different molar ratios of BMOV and VOSO₄ were used to determine binding constants; at 25 °C the binding constants of BMOV to the C- and N-lobes of apo-hTf were found to be 3 (±1) × 10⁵ and 1.8 (±0.7) × 10⁵ M⁻¹, respectively. The corresponding values for VOSO₄ were 1.7 (±0.3) × 10⁵ and 7 (±2) × 10⁴ M⁻¹. The results show that the vanadium species initially presented as either BMOV or VOSO₄ had similar affinities for human serum transferrin due to oxidation of solvated vanadyl(IV) prior to complexation to transferrin. Binding of metavanadate () was confirmed by DSC and isothermal titration calorimetry (ITC) experiments of the interaction between sodium metavanadate (NaVO₃) and hTf.     

Some biologically active oxovanadium(IV) complexes of triazole derived Schiff bases: their synthesis,characterization and biological properties

A series of biologically active oxovanadium(IV) complexes of triazole derived Schiff bases L₁–L₅ have been synthesized and characterized by their physical, analytical, and spectral data. The synthesized ligands potentially act as bidentate, in which the oxygen of furfural and nitrogen of azomethine coordinate with the oxovanadium atom to give a stoichiometry of vanadyl complexes 1:2 (M:L) in a square-pyramidal geometry. In vitro antibacterial and antifungal activities on different species of pathogenic bacteria (E. coli, S. flexneri, P. aeruginosa, S. typhi, S. aureus, and B. subtilis) and fungi (T. longifusus, C. albicans, A. flavus, M. canis, F. solani, and C. glabrata) have been studied. All compounds showed moderate to significant antibacterial activity against one or more bacterial strains and good antifungal activity against most of the fungal strains. The brine shrimp bioassay was also carried out to check the cytotoxicity of coordinated and uncoordinated synthesized compounds.     

Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV)

Vanadate has been recognized as a specific and potent phosphatase inhibitor since its structure is similar to that of phosphate. In this study, we measured the inhibition of glutathione S-transferase-tagged protein tyrosine phosphatase 1B (GST-PTP1B) and alkaline phosphatase (ALP) by the insulin enhancing compounds, bis(maltolato)oxovanadium(IV) (BMOV). The results showed that the activity of GST-PTP1B was reversibly inhibited by solutions of BMOV with an IC₅₀ value of 0.86 ± 0.02 μM. Steady state kinetic studies showed that inhibition of GST-PTP1B by BMOV was of a mixed competitive and noncompetitive type. In addition, incubation of GST-PTP1B with BMOV showed a time-dependent biphasic inactivation of the protein. On the other hand, the inhibitory behavior of BMOV on ALP activity was reversible and competitive with an IC₅₀ value of 32.1 ± 0.6 μM. Incubation with BMOV did not show biphasic inactivation of ALP. The reversible inhibition of GST-PTP1B by BMOV is more potent than that of ALP, but solutions of BMOV inhibited both enzymes. This data support the suggestion that mechanisms for the inhibitory effects of BMOV on GST-PTP1B and ALP are very different.     

Ternary oxovanadium(IV) complexes with amino acid-Schiff base and polypyridyl derivatives: synthesis, characterization, and protein tyrosine phosphatase 1B inhibition

To investigate the structure-activity relationship of vanadium complexes in inhibiting protein tyrosine phosphatase1B (PTP1B), eight mixed-ligand oxovanadium(IV) complexes, [V^IVO(SalAla)(NN)] (H₂SalAla for salicylidene alanine, NN for N,N′-donor heterocyclic base, namely, 2,2′-bipyridine (bpy, 1), 1,10-phenanthroline (phen, 2), dipyrido[3,2-d:2′,3′-f]quinoxaline (dpq, 3), dipyrido[3,2-a:2′,3′-c]phenazine (dppz, 4)), [V^IVO(SalLys)(dpq)] (5), [V^IVO(SalLys)(dppz)] (6), [V^IVO(SalAsp)(dppz)], (7) and [V^IVO(SalTrp)(dppz)] (8)), of which 3-8 are new, have been prepared and characterized by elemental analysis, infrared, UV-visible, electrospray ionization mass spectrometry and conductivity. The molar conductance data confirmed the non-electrolytic nature of the complexes in DMSO solution. The coordination in [V^IVO (SalAla)(phen)] (2) was confirmed by X-ray crystal structure analysis. The oxidation state of V(IV) with d¹ configuration in 2 was confirmed by EPR. The speciation of VO-SalAla-phen in aqueous solution was investigated by potentiometric pH titrations. The results indicate that the main species are two ternary complexes at the pH range 7.0-7.4. Biochemical assays demonstrate that the mixed-ligand oxovanadium(IV) complexes are potent inhibitors of PTP1B with IC₅₀ values in the range of 62-597 nM, approximately 3-10 fold weaker in potency than those of similar mixed-ligand oxovanadium(IV) complexes of salicylidene anthranilic acid (SAA) derivative with polypyridyl ligands, except complex 8, which exhibits comparable or better inhibition activity than those of the mixed-ligand oxovanadium(IV) complexes of SAA derivative with polypyridyl ligands. The results demonstrate that the structures of vanadium complexes influence the PTP1B inhibition activity. Kinetics assays reveal that complex 2 inhibits PTP1B in a competitive manner.     

Syntheses and crystal structures of dimethyltin (IV) derivatives with 2,6-pyridinedicarboxylic acid

A novel cyclic dimethyltin complex [Me₂Sn(2,6-pdc)]₃ (1) (2,6-pdc = 2,6-pyridinedicarboxylate) was synthesized by the reaction of dimethyltin (IV) dichloride and 2,6-pyridinedicarboxylate acid in methanol under solvothermal conditions (150 °C). However, under room temperature (25 °C), we obtained a ladder complex [Me₂Sn(2,6-pdc)]₂(MeOH)₂ (2). Characterization of complexes 1 and 2 was achieved using elemental analysis, IR, ¹H, ¹³C and ¹¹⁹Sn NMR spectra and X-ray diffraction. X-ray data of 1 revealed that it was an unusual cyclic complex with a discrete cyclotrinuclear unit, in which the 12-membered cyclic cavity is almost completely planar. X-ray data of 2 showed that it was a ladder complex, in which a crystallizing methanol molecule is found in each formula unit.     

Synthesis, characterisation and insulin-mimetic activity of oxovanadium(IV) complexes with amidrazone derivatives

The complexation of VO(2+) ion by ten acetamidrazone and 2-phenylacetamidrazone derivatives (L) was studied. Sixteen novel VO(2+) complexes were synthesised and characterised through the combined application of analytical and spectroscopic (EPR (electron paramagnetic resonance), FT-IR and diffuse reflectance electronic absorption) techniques. Eight are 1:2 species of composition [VOL(2)]SO(4) x xH(2)O and eight are 1:1 species with formula [VOL(SO(4))](n) x xH(2)O. The experimental data suggest a bidentate coordination mode for L with the donor set formed by the imine nitrogen and the carbonyl oxygen. EPR spectra indicate a square-pyramidal geometry for the 1:1 complexes and a penta-coordinated geometry intermediate between the square-pyramid and the trigonal-bipyramid for the 1:2 species. The hyperfine coupling constant along z axis, A(z), of the 1:2 complexes exhibits a marked reduction with respect to the predicted value (approximately 148x10(-4)cm(-1) vs. approximately 170x10(-4)cm(-1)). IR spectroscopic evidence supports the presence of sulphate as a counter-ion in the 1:2, and as a bridging bidentate ligand in the 1:1 complexes. Insulin-mimetic tests on modified fibroblasts, based on a modified MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazoliumbromide) assay, performed on three of the bis-chelated and eight of the mono-chelated derivatives, indicate that they are biologically active. The similar hydro/lipophilicity and the lack of ligand substituents recognizable by cell membrane receptors prevent substantial differentiation in the insulin-mimetic action.     

DNA cleavage,binding and intercalation studies of drug-based oxovanadium(IV) complexes

The complexes of oxovanadium(IV) with ciprofloxacin and various uni-negative bidentate ligands have been prepared and their structure investigated using spectral, physicochemical and elemental analyses. The viscosity measurement suggest that the complexes bind to DNA by intercalation. The DNA binding efficacy was determined using absorption titration to obtain the binding constant (K_b). The DNA cleavage efficacy was determined using gel electrophoresis. The DNA binding and cleavage efficacy were increased in the complexes relative to the parental ligands and metal salts. Antibacterial activity has been assayed against two Gram^{( ? ve)} i.e. Escherichia coli, Pseudomonas aeruginosa and three Gram^{( + ve)} Staphylococcus aureus, Bacillus subtilis, Serratia marcescens microorganisms using the doubling dilution technique. The results show a significant increase in antibacterial activity in the complexes compared with parental ligands and metal salts.     

The solution structure of bis(acetylacetonato)oxovanadium(IV)

The behaviour of the bis-chelated oxovanadium(IV) complexes formed by acetylacetone (acac) and five of its derivatives was re-examined through a combination of spectroscopic methods in different solvents. It has been found that the complexes are penta-coordinated with a geometry close to the square pyramid and maintain in solution the same structure as in the solid state. The results rule out a cis-trans isomerism of the species VOL₂S (L = acac or derivative, S = solvent) in solution. Depending on the coordinating ability of the solvent a sixth molecule can be bound, more or less strongly, to the free axial position of the complexes. The combined application of the electronic absorption and IR spectroscopies allows to establish if the complexes in solution are penta- or hexa-coordinated.     

In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats

In this study, the in vivo effects of insulin and chronic treatment with bis(maltolato)oxovanadium (IV) (BMOV) on protein kinase B (PKB) activity were examined in the liver and skeletal muscle from two animal models of diabetes, the STZdiabetic Wistar rat and the fatty Zucker rat. Animals were treated with BMOV in the drinking water (0.75–1 mg/ml) for 3 (or 8) weeks and sacrificed with or without insulin injection. Insulin (5 U/kg, i.v.) increased PKB activity more than 10fold and PKB activity more than 3fold in both animal models. Despite the development of insulin resistance, insulininduced activation of PKB was not impaired in the STZdiabetic rats up to 9 weeks of diabetes, excluding a role for PKB in the development of insulin resistance in type 1 diabetes. Insulin-induced PKB activity was markedly reduced in the skeletal muscle of fatty Zucker rats as compared to lean littermates (fatty: 7fold vs. lean: 14fold). In contrast, a significant increase in insulinstimulated PKBa activity was observed in the liver of fatty Zucker rats (fatty: 15.7fold vs. lean: 7.6fold). Chronic treatment with BMOV normalized plasma glucose levels in STZdiabetic rats and decreased plasma insulin levels in fatty Zucker rats but did not have any effect on basal or insulininduced PKB and PKB activities. In conclusion (i) in STZdiabetic rats PKB activity was normal up to 9 weeks of diabetes; (ii) in fatty Zucker rats insulininduced activation of PKB (but not PKB) was markedly altered in both tissues; (iii) changes in PKB activity were tissue specific; (iv) the glucoregulatory effects of BMOV were independent of PKB activity.     

Manganese(II) and zinc(II) compounds via amino acid derivatives: Effects of temperature and solvents

To investigate the influence of temperature and the ratios of solvents on the design and synthesis of metal-organic frameworks (MOFs), we have synthesized and structurally characterized a series of supramolecular assemblies based on different amino acid derivatives and nitrogen-containing heterocyclic ligands, namely [Mn(phen)₂(phth)(H₂O)]·4H₂O (1), [Mn(phen)₂(HL1)₂]·3.5H₂O (2), [Zn(bpp)₂(L-Me)₂] (3), and [Zn(bpp)(L-Me)₂] (4) (H₂phth = phthalic acid, H₂L¹ = phthalyl-l-valine, H₂L = (+)-N-tosyl-l-glutamic acid, phen = 1,10-phenanthroline, bpp = 1,3-bis(4-pyridyl)propane, and L-Me = C₁₂H₁₃NO₆S-CH₃). Compounds 1 and 2, which are assembled through noncovalent interactions, were obtained by controlling the temperature. In 1, π-π stacking and hydrogen-bonding interactions lead to stacking in a 3D supramolecular network, while in 2, π-π stacking interactions form 1D chains that extend along the c-axis. Depending on the solvents employed, compounds 3 and 4 could be generated, with a 1D bpp-connected Zn-bpp-Zn double chain that is further hydrogen-bonded into a 2D network that extends parallel to the ac plane in 3, and a single chain in 4.     

Synthesis, characterization and crystal structure of manganese (IV) complex derived from salicylic acid

The binuclear manganese (IV) [Mn₂(Hsal)₄(OH)₄] (H₂sal = salicylic acid) complex has been obtained from a complex reaction mixture in methanol consisting of Mn(II)(OAc)₂ · 4H₂O, GS ( a reagent obtained by refluxing glycine and salicylaldehyde in 1:1 molar ratio in methanol), monosodium salicylate and pyridine. The compound contains a distorted octahedral MnO₆ coordination unit of potential importance to high oxidation state manganese bimolecules.     

Vanadocene complexes of amino acids containing secondary amino group: The first evidence of O,O-bonded carboxylic group to vanadocene(IV) moiety

Reaction of vanadocene dichlorides (Cp₂VCl₂ and (η⁵-C₅H₄Me)₂VCl₂) with amino acids containing secondary amino groups gives three types of complexes: a) compounds with N,O-bonded amino acid, b) O-bonded amino acids and c) O,O-bonded amino acid. The complexes with N,O-bonded amino acid and O-bonded amino acids were observed in the case of l-proline and N-methylglycine (NMG). Reactions with N-phenylglycine (NPG) give O,O-chelates as the sole products. All three types of the complexes were characterized by spectroscopic methods. Structures of [(η⁵-C₅H₄Me)₂V(O-Pro)][BPh₄], [Cp₂V(O-Pro)₂][PF₆]₂, [Cp₂V(N,O-NMG)][BPh₄]·MeOH, [(η⁵-C₅H₄Me)₂V(N,O-NMG)][BPh₄]·MeOH, [Cp₂V(O-NMG)₂][Cl]₂·2H₂O, [(η⁵-C₅H₄Me)₂V(O-NMG)₂][Cl]₂·H₂O and [(η⁵-C₅H₄Me)₂V(O,O-NPG)][BPh₄] were determined by X-ray crystallography.     

Synthesis, structure and solution chemistry of quaternary oxovanadium(V) complexes incorporating hydrazone ligands

[V^IVO(acac)₂] reacts with an equimolar amount of benzoyl hydrazone of 2-hydroxyacetophenone (H₂L¹) or 5-chloro-2-hydroxyacetophenone (H₂L²) in the presence of excess pyridine (py) in methanol to produce the quaternary [V^VO(L¹)(OCH₃)(py)] (1) and [V^VO(L²)(OCH₃)(py)] (2) complexes, respectively, while under similar condition, the benzoyl hydrazones of 2-hydroxy-5-methylacetophenone (H₂L³) and 2-hydroxy-5-methoxyacetophenone (H₂L⁴) afforded only the methoxy bridged dimeric [V^VO(L³/L⁴)(OCH₃)]₂ complexes. The X-ray structural analysis of 1 and 2 indicates that the geometry around the metal is distorted octahedral where the three equatorial positions are occupied by the phenolate-O, enolate-O and the imine-N of the fully deprotonated hydrazone ligand in its enolic form and the fourth one by a methoxide-O atom. An oxo-O and a pyridine-N atom occupy two axial positions. Quaternary complexes exhibit one quasi-reversible one-electron reduction peak near 0.25 V versus SCE in CH₂Cl₂ and they decompose appreciably to the corresponding methoxy bridged dimeric complex in CDCl₃ solution as indicated by their ¹H NMR spectra. These quaternary VO³⁺ complexes are converted to the corresponding -complexes simply on refluxing them in acetone and to the -complexes on reaction with KOH in methanol. An equimolar amount of 8-hydroxyquinoline (Hhq) converts these quaternary complexes to the ternary [V^VO(L)(hq)] complexes in CHCl₃.     

Improvement of diabetes, obesity and hypertension in type 2 diabetic KKAy mice by bis(allixinato)oxovanadium(IV) complex

Previously, we found that bis(allixinato)oxovanadium(IV) (VO(alx)(2)) exhibits a potent hypoglycemic activity in type 1-like diabetic mice. Since the enhancement of insulin sensitivity is involved in one of the mechanisms by which vanadium exerts its anti-diabetic effects, VO(alx)(2) was further tested in type 2 diabetes with low insulin sensitivity. The effect of oral administration of VO(alx)(2) was examined in obesity-linked type 2 diabetic KKA(y) mice. Treatment of VO(alx)(2) for 4 weeks normalized hyperglycemia, glucose intolerance, hyperinsulinemia, hypercholesterolemia and hypertension in KKA(y) mice; however, it had no effect on hypoadiponectinemia. VO(alx)(2) also improved hyperleptinemia, following attenuation of obesity in KKA(y) mice. This is the first example in which a vanadium compound improved leptin resistance in type 2 diabetes by oral administration. On the basis of these results, VO(alx)(2) is proposed to enhance not only insulin sensitivity but also leptin sensitivity, which in turn improves diabetes, obesity and hypertension in an obesity-linked type 2 diabetic animal.     

Synthesis, characterization, crystal structure and antitumor activity of organotin(IV) compounds bearing ferrocenecarboxylic acid

Four new organotin(IV) complexes [(Bu₃Sn)(FcCOO)]_n (1), [(μ-Bu₂Sn)₂(μ-Bu₂SnFcCOO)₂(μ₃-O)₂(μ-OCH₃)₂]₂ (2), [Ph₃Sn(FcCOO)(H₂O)](phen) (3) and [{Ph₃Sn(FcCOO)}₂(4,4′-bipy)] (4) [Fc = (η⁵-C₅H₅)Fe(η⁵-C₅H₄)] have been synthesized and characterized by elemental analyses, IR, (¹H and ¹³C) NMR spectra and X-ray single-crystal diffraction analyses. The structure analyses show that all tin atoms in complexes 1-4 are five-coordinated with trigonal bipyramid geometry. Complexes 1-4 and FcCOOH undergo reversible one-electron oxidations in methanol solution. The antitumor activities of complexes 1-4 have also been tested. Complexes 1 and 2 exhibit medium activity towards P388 cell lines and Hela cell lines. Complexes 3 and 4 exhibit medium activity towards P388 cell lines but strong activity towards Hela cell lines. This may result from complexes 3 and 4 including the neutral molecules 1,10-phenanthroline and 4,4′-bipy.     

Studies of mononuclear and dinuclear complexes of dibromodimethylplatinum(IV): Preparation, characterization and crystal structures

A number of complexes of the types [PtBr₂Me₂(N^?N)] (N^?N = 4,4′-di-Me-2,2′-bpy (1); 4,4′-di-t-Bu-2,2′-bpy (2); 2,2′-bpz (3); bpym (4)) and [PtBr₂Me₂(L)₂] (L = H-pz (5); 4-Me-H-pz (6); H-idz (7); H-im (8); H-bim (9); quaz (10)) are reported. Characterization by NMR (¹H, ¹³C and ¹⁹⁵Pt), IR and EI-MS is given. In addition, crystal structures of several of these complexes are described. Furthermore, interactions within these structures including intramolecular hydrogen bonding and π-π stacking interactions are reported. The reactivity of selected mononuclear complexes was investigated and yielded two dinuclear complexes [PPh₄][(PtBrMe₂)₂(μ-Br)(μ-pz)₂] (11) and [(PtBr₂Me₂)₂(μ-bpym)] (12), respectively. The latter complex is accompanied by a solid-state structure. Finally, the thermal stability of all complexes is reported.     

Investigation on the coordination modes: Syntheses, characterization and crystal structures of diorganotin (IV) dichloride with 4(5)-imidazoledithiocarboxylic acid

A series of diorganotin (IV) complexes of the types of R₂SnCl(SSCC₃H₃N₂) (R = CH₃1, ⁿBu 2, C₆H₅3 and C₆H₅CH₂4), R₂Sn(SSCC₃H₃N₂)₂ (R = CH₃5, ⁿBu 6, C₆H₅7 and C₆H₅CH₂8) and R₂Sn(SSCC₃H₂N₂) (R = CH₃9, ⁿBu 10, C₆H₅11 and C₆H₅CH₂12) have been obtained by reactions of 4(5)-imidazoledithiocarboxylic acid with diorganotin (IV) dichlorides in the presence of sodium ethoxide. All complexes are characterized by elemental, IR, ¹H, ¹³C and ¹¹⁹Sn NMR spectra analyses. Also, the complexes 1, 7 and 9 are characterized by X-ray crystallography diffraction analyses, which reveal that the complex 1 is monomeric structure with five-coordinate tin (IV) atom, the complex 7 is monomeric structure with six-coordinate tin (IV) atom and the complex 9 is one-dimensional chain with five-coordinate tin (IV) atom.